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> 0.05, ANOVA). Postmortem evaluation
revealed that 2-3 hepatic veins were
transected by injury type 1, 1-2 portal vein
branches plus 1 hepatic vein were transected
by injury type 3 (LLL transection).
Conclusions: The hemorrhage severity of the 
central stellate injury was inadequate, while 
hemorrhage from excision of a proximal 
branch of the portal vein appeared to be too 
severe (i.e., the subjects died too quickly). 
Near-transection of the hepatic LLL at its base 
appeared to yield hemorrhage of appropriate 
severity, as indicated by the 40% 1-hour 
mortality and intermediate values for MAP, 
blood loss, and other variables. Our plan is to 
use this latter injury model in the development 
of therapies for noncompressible truncal 
hemorrhage. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.047
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Background: The use of exogenous 
testosterone has become more prevalent in 
recent years but the effects of such use in 
regards to potential cerebrovascular disease 
have yet to come to a conclusion. In this case 
report, we discuss a patient who suffered 
an ischemic stroke due to testosterone 
supplementation.
Case presentation: A middle-aged 
patient with history of hypertension and 
hyperlipidemia that presented with falls, 
difficulty performing simple tasks and slurred 
speech. Patient had been taking testosterone 
injections every 6 months for the prior 2 years 
for loss of energy and reported low levels. 
Lab work revealed a hemoglobin of 20 g/dL 
and a hematocrit of 51.5%. MRI of the brain 
showed a left striatocapsular ischemic infarct. 
He was given the diagnosis of ischemic stroke 
due to polycythemia and thrombus formation 
secondary to testosterone supplementation. 
Discussion: Testosterone and 
dihydrotestosterone (DHT) has both 
protective and adverse effects. Both low and 
high levels of testosterone and DHT have an 
association with ischemic stroke and there 
may be an optimal level that is safe. 
Conclusion: The risk of ischemic stroke may 
be related to testosterone and DHT levels but 
no clear guidelines exist on optimal levels 
in supplementation. Thus, clinicians should 
be aware of the potential risk and monitor 
androgen and hematocrit levels. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.048
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Objective: To assess the effectiveness of 
treatment for status epilepticus (SE) at UNMC 
and determine patient health outcomes related 
to the delayed control of seizures 
Design/Methods: Retrospective chart 
review was performed on 1565 adult 
patients who underwent continuous video 
electroencephalography (cvEEG) for 
suspected seizures between January 1, 2012 
and February 28, 2018. 
Results: 49 patients had and were treated for 
64 incidences of convulsive or nonconvulsive 
SE recorded on cvEEG or clinical seizures 
longer than 5 min which were documented by 
a neurologist. Among 64 cases, 55 incidences 
required the second AED treatment, and 
40 out of 55 cases were treated with the 
third AED subsequently. The mean seizure 
detection-to-needle time for the first, 
second, and third antiepileptic drugs were 
167, 239, and 297 minutes, respectively. 
Benzodiazepines were administered as the 
first AED in only 46 % of all treated cases. 
The duration of the hospital stays in patients 
treated with the first AED within 60 min after 
seizure detection was shorter compared to 
those whose treatment was delayed (23.0 vs. 
33.6 days, p=0.41). The mortality rate in the 
former group was lower than that in the group 
which did not receive AEDs within 60 min 
(28.6 vs. 53.6%, p=0.02). 
Conclusion: The current treatment approaches 
for SE at UNMC are inefficient with 
significant delay in delivery of medications 
after seizure detection; they may contribute 
to the prolonged hospital stay and increased 
mortality. In order to improve patient care, the 
existing protocol for the treatment of SE at 
UNMC must be revised. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.049
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Background: VNS Therapy has demonstrated 
overall cost savings in patients with drug-
51 
resistant epilepsy. The overall goal of this 
project is to evaluate the clinical and cost 
effectiveness of the Aspire SR 106 VNS 
(Vagus Nerve Stimulator) system, using 
retrospective patient data. We anticipate 
the extra dimension of closed-loop 
autostimulation in the Aspire 106 model will 
demonstrate more efficient utilization of 
health care resources. 
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